During a meeting, President Trump suggested to Novo Nordisk’s CEO that the company give the government a stake, a request that was ignored. This followed Trump’s history of the government taking ownership in other companies. The president’s push for a stake was almost overshadowed by a patient collapsing during the press conference, which was meant to be centered around Trump’s promise to lower drug prices. This promise, along with potential government ownership, would create further pressure on Trump, although his economic policies might hinder efforts to reduce prescription costs.
Read More
Novo Nordisk has ended its partnership with telehealth provider Hims & Hers Health, citing concerns about deceptive marketing practices related to weight-loss drugs. The collaboration, initiated in April, enabled Hims & Hers to offer Wegovy, a branded weight management medication, at a discounted price. However, Novo Nordisk took issue with Hims & Hers’ ongoing promotion of compounded versions of semaglutide, the active ingredient in Wegovy, which are not FDA-approved and were only permitted temporarily due to a shortage that has since been resolved. Novo Nordisk emphasized its commitment to taking action against companies involved in “illegal sham compounding” that endangers public health.
Read More
Novo Nordisk’s recent announcement to slash US list prices of two insulin products by more than 70% is undeniably a significant event. This dramatic price reduction, while seemingly a benevolent act, is a complex issue with multiple contributing factors beyond simple corporate altruism.
The timing of this price cut is intriguing, coinciding with the Biden administration’s negotiations with pharmaceutical companies to lower Medicare drug prices. While the full effects of these negotiations won’t be felt until 2026, Novo Nordisk’s proactive move suggests a response to the broader pressure for affordability in the insulin market. It’s tempting to see this as a direct result of political pressure, and perhaps it partially is, but it’s likely more nuanced than that.… Continue reading
As a healthcare professional, I have always been appalled by the exorbitant prices that pharmaceutical companies charge for life-saving medications in the United States. The recent controversy surrounding Novo Nordisk’s pricing of Ozempic and Wegovy sheds light on the profit-driven motives that underlie the pharmaceutical industry. It is truly disheartening to see medications that could potentially improve the health and well-being of individuals being priced out of reach for many Americans.
Novo Nordisk’s CEO, Lars Fruergaard Jørgensen, has defended the high U.S. prices of these drugs by claiming that they are ‘helping’ reduce the cost of obesity in the long run.… Continue reading
John Q. Hosedrinker 
Matt Underwood